Tag: Cybin Corp - Page 4 - Psychedelic Alpha

Read more about the article Cybin Announces Positive Pre-Clinical Results With Multiple Proprietary Psychedelic Molecules and Adelia Milestone Achievement

Cybin Announces Positive Pre-Clinical Results With Multiple Proprietary Psychedelic Molecules and Adelia Milestone Achievement

Post published:June 29, 2021
Post category:Press Release

Read more about the article Cybin Announces Former FDA Psychiatry Division Director Dr. Thomas Laughren has Joined Clinical Advisory Board

Cybin Announces Former FDA Psychiatry Division Director Dr. Thomas Laughren has Joined Clinical Advisory Board

Post published:June 24, 2021
Post category:Press Release

Read more about the article Cybin Announces Completion of its 51st Pre-Clinical Psychedelic Molecule Study

Cybin Announces Completion of its 51st Pre-Clinical Psychedelic Molecule Study

Post published:June 22, 2021
Post category:Press Release

Read more about the article Cybin Selects Anxiety Disorder Indications for Proprietary Psychedelic Molecule CYB004

Cybin Selects Anxiety Disorder Indications for Proprietary Psychedelic Molecule CYB004

Post published:June 16, 2021
Post category:Press Release

Read more about the article Cybin Announces Sponsorship of a Kernel Flow Feasibility Study to Measure Ketamine’s Psychedelic Effects on Cerebral Cortex Hemodynamics

Cybin Announces Sponsorship of a Kernel Flow Feasibility Study to Measure Ketamine’s Psychedelic Effects on Cerebral Cortex Hemodynamics

Post published:June 1, 2021
Post category:Press Release

Read more about the article Cybin Files an International Patent Application Further Strengthening its Psychedelic Derivative Drug Development Candidates Across 153 Global Jurisdictions

Cybin Files an International Patent Application Further Strengthening its Psychedelic Derivative Drug Development Candidates Across 153 Global Jurisdictions

Post published:May 26, 2021
Post category:Press Release

Read more about the article Cybin Files its 12th Patent Further Strengthening IP Portfolio of Novel Psychedelic Molecules and Delivery Mechanisms

Cybin Files its 12th Patent Further Strengthening IP Portfolio of Novel Psychedelic Molecules and Delivery Mechanisms

Post published:May 20, 2021
Post category:Press Release

Read more about the article Cybin Granted IRB Approval for Phase II Clinical Trials of its Sublingual Psilocybin Formulation for the Treatment of Major Depressive Disorder

Cybin Granted IRB Approval for Phase II Clinical Trials of its Sublingual Psilocybin Formulation for the Treatment of Major Depressive Disorder

Post published:May 18, 2021
Post category:Press Release

Read more about the article Cybin Selects Alcohol Use Disorder Indication for Psychedelic Molecule CYB003

Cybin Selects Alcohol Use Disorder Indication for Psychedelic Molecule CYB003

Post published:April 26, 2021
Post category:Press Release

Read more about the article Cybin Demonstrates Proof of Concept of Its Deuterated Tryptamines for the Treatment of Depression and Addiction

Cybin Demonstrates Proof of Concept of Its Deuterated Tryptamines for the Treatment of Depression and Addiction

Post published:April 21, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.